Evidence map›Paper›PMID 40517273›Full record

ArticleCardiovascular diabetology2025

Beyond overweight, visceral adiposity is associated with estimation of cardiovascular risk in patients living with type 1 diabetes: findings from the SFDT1 cohort.

Laurence Salle, Jean-Baptiste Julla, Guy Fagherazzi, Pierre Gourdy, Erika Bezerra Parente, Hélène Hanaire, Sopio Tatulashvili, Emmanuel Disse, Sylvia Franc, Samy Hadjadj and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Obesity paradox in individuals with type 1 diabetes.Frontiers in clinical diabetes and healthcare · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Laurence SalleInserm 1094 & IRD270, Limoges University Hospital, Limoges, France. laurence.salle@unilim.fr.
Jean-Baptiste JullaUniversité Paris Cité, CNRS, INSERM, Institut Necker Enfants Malades-INEM, 75015, Paris, France.
Guy FagherazziDeep Digital Phenotyping Research Unit, Department of Precision Health (GAA, GF), Luxembourg Institute of Health, 1A-B, Rue Thomas Edison, L-1445, Strassen, Luxembourg.
Pierre GourdyDepartment of Diabetology, Metabolic Diseases and Nutrition, Toulouse University Hospital, Toulouse, France.
Erika Bezerra ParenteFolkhälsan Research Center, Biomedicum Helsinki, Finland.
Hélène HanaireDepartment of Diabetology, Metabolic Diseases and Nutrition, Toulouse University Hospital, Toulouse, France.
Sopio TatulashviliDepartment of Endocrinology-Diabetology-Nutrition, AP-HP, Avicenne Hospital, Université Paris 13, Sorbonne Paris Cité, CRNH-IdF, CINFO, Bobigny, France.
Emmanuel DisseDepartment of Endocrinology, Diabetes and Nutrition, Hospices Civils de Lyon, Hôpital Lyon Sud, 69390, LyonLyon, France.
Sylvia FrancDepartment of Endocrinology, Sud Francilien Hospital, DiabetologyCorbeil-Essonnes, France.
Samy HadjadjThorax Institute, CNRS, INSERM, Nantes University Hospital Center, Nantes University, Nantes, France.
Etienne LargerDiabetology Department, Cochin Hospital, AP-HP, Paris, France.
Caroline SanzDepartment of Diabetology, and Endocrinology Clinique Pasteur, Toulouse, France.
Patricia VaduvaDepartment of Endocrinology, Diabetes and Nutrition, Rennes University Hospital, 35000, Rennes, France.
René ValeroAix Marseille Univ, APHM, INSERM, INRAE, University Hospital La Conception, C2VN, Marseille, France.
Amélie BonnefondInserm/CNRS UMR 1283/8199, Pasteur Institute of Lille, EGID, Lille, France.
Emmanuel CossonDepartment of Endocrinology-Diabetology-Nutrition, AP-HP, Avicenne Hospital, Université Paris 13, Sorbonne Paris Cité, CRNH-IdF, CINFO, Bobigny, France.
Gloria A AguayoDeep Digital Phenotyping Research Unit, Department of Precision Health (GAA, GF), Luxembourg Institute of Health, 1A-B, Rue Thomas Edison, L-1445, Strassen, Luxembourg.
Jean-Pierre RivelineUniversité Paris Cité, CNRS, INSERM, Institut Necker Enfants Malades-INEM, 75015, Paris, France.
SFDT1 group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

INTRODUCTION &

objectivesAs in the general population, people living with type 1 diabetes (PWT1D) are faced with overweight and obesity, which contribute to cardiovascular (CV) risk. However, the role of visceral adiposity, due to its adverse metabolic profile, should also be addressed in PWT1D. We aimed to assess the 10-year CV risk of PWT1D according to body mass index (BMI) and waist-to-height ratio (WHtR), a parameter for estimating visceral adiposity.

methodsIn this cross-sectional study, PWT1D in primary CV prevention from the SFDT1 cohort were categorized by BMI status, either normal (18.5-24.9 kg/m

resultsThe study included 1,482 patients; 49.9% had a normal BMI, and 50.1% a BMI ≥ 25 kg/m

conclusionIn PWT1D in condition of primary CV prevention, visceral adiposity, assessed by WHtR, is a more robust marker of estimated 10-year CV risk than overweight/obesity status in both men and women.

Indexed as

AdiposityCardiovascular DiseasesDiabetes Mellitus, Type 1Intra-Abdominal FatObesity, AbdominalAdultBody Mass IndexCross-Sectional StudiesFemaleHeart Disease Risk FactorsHumansMaleMiddle AgedPrognosisRisk AssessmentTime FactorsAdiposity distributionBody mass indexCardiovascular riskRegistrySexType 1 diabetesWaist circumference

Identifiers

PMID40517273
PMCPMC12166620

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.